Abstract: Provided are a quantum dot tandem solar cell and a preparation method thereof. The quantum dot tandem solar cell includes a front cell, a transparent conductive middle layer, a rear cell, and a counter electrode. The front cell includes a conductive substrate, a first oxide semiconductor film, and a first semiconductor quantum dot film. The transparent conductive middle layer is an indium tin oxide (ITO) film. The rear cell includes a second oxide semiconductor film and a second semiconductor quantum dot film. The counter electrode is a metal electrode.

Abstract: A medical device undercarriage including a pair of front wheels, a pair of rear wheels, a first position sensitive detector located between the pair of front wheels, a second position sensitive detector located between the pair of rear wheels, and a controller. The controller is operable to calculate a gear ratio of the rear wheels according to a position of the first position sensitive detector and a position of the second position sensitive detector.

Abstract: The invention provides combination therapy involving the inhibition of lipoprotein-associated phospholipase A2 (Lp-PLA2) and a second therapy. To facilitate the practice of the invention, the invention also provides a composition comprising a first agent comprising an Lp-PL2 inhibitory molecule, a second agent, and a pharmaceutically-acceptable carrier. In certain embodiments, the second agent comprises an amyloid-targeting molecule, an agent that lowers the level of amyloid in the brain or body, a tau-targeting molecule, a vasculature-targeting molecule, an inflammation-targeting molecule, and/or a molecule that modulates a mechanism of action that is orthogonal from Lp-PLA2 inhibition. Combinations of such second agents are contemplated as well.

Abstract: Processes for preparing a catalyst is provided that includes addition of a phosphorous containing component at one or more points are provided herein. The resulting catalysts are suitable for use in a fluidized catalytic cracker (FCC) or other similar chemical processing unit. Processes according to embodiments of the present technology are suitable for use in existing and commercial-scale facilities, and may result in reduced expense, while providing energy-saving and environmental benefits.

Abstract: The present disclosure provides a method for growing scintillation crystals with multi-component garnet structure. According to the method, through weight compensating for reactants, introducing a flowing gas, adopting a new temperature field device, and optimizing process parameters, problems such as component deviation and crystal cracking during the crystal growth can be solved to a certain extent, and grown crystals have consistent performance and good repeatability.

Abstract: The disclosure provides a display apparatus and a method. In response to a first command from a user, the display apparatus can obtain media data of a target channel and execute a first process and a second process in parallel. The first process can include demultiplexing the data segment to obtain ES data and obtaining first metadata information according to the encryption data and first ES data. The second process can include predicting second metadata information according to the attribute parameter and the encryption data. Based on that the second metadata information is generated before the first metadata information, the display apparatus can initialize a decoder according to the second metadata information, decode the ES data via the initialized decoder to obtain decoded ES data, and display a program image of the target channel on the display according to the decoded ES data.

Abstract: The embodiments of the present disclosure provide a method and apparatus for training an SVM model, a device and a computer-readable storage medium. The method comprises steps of: acquiring a dataset; loading the dataset; predicting the best storage format of the dataset online through an automatic tuning framework, and performing format conversion; and, executing an SMO algorithm to train an SVM model. In this way, the best data storage format and algorithm can be automatically selected according to the input dataset; in a global loop level, a large number of more efficient matrix multiplication operations are performed on the basis of the best data storage format to calculate a kernel matrix; and, in a local SMO solver level, finer memory optimization is performed by the register communication technology and the combined memory access method of the GPU, and the calculation resources of the hardware platform are fully utilized.

Abstract: Provided are a driver and a transmitter. The driver includes: an n-type metal-oxide-semiconductor field-effect transistor differential circuit, a p-type metal-oxide-semiconductor field-effect transistor differential circuit and a power supply. Gate electrodes of the p-type metal-oxide-semiconductor field-effect transistor differential circuit and the n-type metal-oxide-semiconductor field-effect transistor differential circuit receive a first level signal. The p-type and n-type metal-oxide-semiconductor field-effect transistor differential circuits convert the first level signal into a second level signal used by an actuator. Drain electrodes of the p-type and n-type metal-oxide-semiconductor field-effect transistor differential circuits output the second level signal.

Abstract: A central architecture diagram construction method includes obtaining a plurality of pieces of entity information and a relationship between the plurality of pieces of entity information, and then determining first entity information, where the first entity information is one of the plurality of pieces of entity information; constructing a central architecture diagram based on the first entity information and the relationship between the plurality of pieces of entity information, and displaying the central architecture diagram, where a central node in the central architecture diagram indicates the first entity information, the central architecture diagram further includes a plurality of ring layers centered on the central node, each ring layer includes at least one node, and nodes at different ring layers have different relationships with the central node.

Abstract: A spatial omics single cell data acquisition method includes: acquiring a dyeing image of a biological sample, and acquiring a visual gene expression image of the biological sample; registering the dyeing image with the visual gene expression image, so as to obtain a registered image; performing cell segmentation on the registered image, so as to obtain a cell mask image; and according to the cell mask image, determining a cell of a background gene molecule of an unknown cell in the visual gene expression image, and marking the cell, so as to obtain a spatial omics molecular expression matrix with a cell mark. Compared with the prior art, the present disclosure relates to obtaining high-precision spatial single cell data by means of a gene expression matrix diagram, and a processing flow involving splicing, registration, segmentation and correction.

Abstract: Provided in the present application are a compound represented by formula (I), a pharmaceutical composition containing the compound, and the use thereof. The compound represented by formula (I) of the present application has a good effect in terms of inhibiting the activity of HPK1.

Abstract: The application relates to a novel salt of compound (II) and a crystalline form thereof, and to a preparation method for the salt and the crystalline form thereof. Additionally, the application provides a pharmaceutical composition comprising a hydrochloride of compound (II), and an application of the salt in the preparation of a drug used for the prevention and treatment of thrombin-mediated and/or thrombin-related diseases.

Abstract: The present disclosure relates to oligonucleotides, in particular antisense oligonucleotides (ASOs) and pharmaceutically acceptable salts thereof, that can hybridize and reduce the expression of APOE pre-mRNA or mRNA. ASOs disclosed herein can reduce translation of APOE protein in mammals (e.g., humans). The present disclosure further relates to methods of treating a disease or disorder in a subject in need thereof by administration of an antisense oligonucleotide disclosed herein. In particular, methods and ASOs described herein can be used for preventing and/or treating human diseases in which the reduction of APOE amount or its activity would be beneficial, including but not limited to neurodegenerative diseases such as Alzheimer's disease (AD), dementia with Lewy bodies (DLB), Parkinson disease dementia (PDD), and those broadly defined as tauopathies and synucleinopathies.